Feasibility of dendritic cell-based vaccine against glioblastoma by using cytoplasmic transduction peptide (CTP)-fused protein antigens combined with anti-PD1

References

• Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014. Neuro Oncol. 2017;19(suppl_5):v1–v88. doi:10.1093/neuonc/nox158.
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96. doi:10.1056/NEJMoa043330.
   PubMed Web of Science ®Google Scholar
• Thomas AA, Fisher JL, Ernstoff MS, Fadul CE. Vaccine-based immunotherapy for glioblastoma. CNS Oncol. 2013;2(4):331–49. doi:10.2217/cns.13.29.
   PubMedGoogle Scholar
• Wen PY, Reardon DA, Armstrong TS, Phuphanich S, Aiken RD, Landolfi JC, Curry WT, Zhu JJ, Glantz M, Peereboom DM. A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma. Clin Cancer Res. 2019;25(19):5799–807. doi:10.1158/1078-0432.CCR-19-0261.
   PubMed Web of Science ®Google Scholar
• van Montfoort N, van der Aa E, Woltman AM. Understanding MHC class I presentation of viral antigens by human dendritic cells as a basis for rational design of therapeutic vaccines. Frontiers Immunol. 2014. 5.
   PubMed Web of Science ®Google Scholar
• Suzuki R, Oda Y, Utoguchi N, Namai E, Taira Y, Okada N, Kadowaki N, Kodama T, Tachibana K, Maruyama K, et al. A novel strategy utilizing ultrasound for antigen delivery in dendritic cell-based cancer immunotherapy. J Control Release. 2009;133(3):198–205. doi:10.1016/j.jconrel.2008.10.015.
   PubMed Web of Science ®Google Scholar
• Shen L, Rock KL. Priming of T cells by exogenous antigen cross-presented on MHC class I molecules. Curr Opin Immunol. 2006;18(1):85–91. doi:10.1016/j.coi.2005.11.003.
   PubMed Web of Science ®Google Scholar
• Kim D, Jeon C, Kim J, Kim M, Yoon C, Choi I, Kim S, Bae Y. Cytoplasmic transduction peptide (CTP): new approach for the delivery of biomolecules into cytoplasm in vitro and in vivo. Exp Cell Res. 2006;312(8):1277–88. doi:10.1016/j.yexcr.2005.12.029.
   PubMed Web of Science ®Google Scholar
• Chauhan A, Tikoo A, Kapur AK, Singh M. The taming of the cell penetrating domain of the HIV Tat: myths and realities. J Control Release. 2007;117(2):148–62. doi:10.1016/j.jconrel.2006.10.031.
   PubMed Web of Science ®Google Scholar
• Huang SF, Liu D-B, Zeng J-M, Yuan Y, Xiao Q, Sun C-M, Li C-L, Tao K, Wen J-P, Huang Z-G. Cloning, expression, purification, distribution and kinetics characterization of the bacterial beta-galactosidase fused to the cytoplasmic transduction peptide in vitro and in vivo. Protein Expr Purif. 2009;68(2):167–76. doi:10.1016/j.pep.2009.06.019.
   PubMed Web of Science ®Google Scholar
• Song LL, Zhuo M, Tang Y, Chen X, Yu Y, Tang Z, Zang G. Ubiquitin-modified hepatitis B virus core antigen effectively facilitates antigen presentation and enhances cytotoxic T lymphocyte activity via the cytoplasmic transduction peptide in vitro. Mol Med Rep. 2015;12(1):289–96. doi:10.3892/mmr.2015.3352.
   PubMed Web of Science ®Google Scholar
• Su HT, Li B, Zheng L, Wang H, Zhang L. Immunotherapy based on dendritic cells pulsed with CTP-FoxM1 fusion protein protects against the development of hepatocellular carcinoma. Oncotarget. 2016;7(30):48401–11. doi:10.18632/oncotarget.10269.
   PubMedGoogle Scholar
• Platten M, Reardon DA. Concepts for Immunotherapies in Gliomas. Semin Neurol. 2018;38(1):62–72. doi:10.1055/s-0037-1620274.
   PubMed Web of Science ®Google Scholar
• Taggart D, Andreou T, Scott KJ, Williams J, Rippaus N, Brownlie RJ, Ilett EJ, Salmond RJ, Melcher A, Lorger M. Anti–PD-1/anti–CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8+ T cell trafficking. Proc Natl Acad Sci U S A. 2018;115(7). E1540-E1549. doi:10.1073/pnas.1714089115.
   PubMed Web of Science ®Google Scholar
• Mohammad MG, Tsai VWW, Ruitenberg MJ, Hassanpour M, Li H, Hart PH, Breit SN, Sawchenko PE, Brown DA. Immune cell trafficking from the brain maintains CNS immune tolerance. J Clinl Inves. 2014;124(3):1228–41. doi:10.1172/JCI71544.
   PubMed Web of Science ®Google Scholar
• Lim M, Xia Y, Bettegowda C, Weller M. Current state of immunotherapy for glioblastoma. Nat Rev Clin Oncol. 2018;15(7):422–42. doi:10.1038/s41571-018-0003-5.
   PubMed Web of Science ®Google Scholar
• Jung S-H, Lee H-J, Lee Y-K, Yang D-H, Kim H-J, Rhee JH, Emmrich F, Lee JJ. A phase I clinical study of autologous dendritic cell therapy in patients with relapsed or refractory multiple myeloma. Oncotarget. 2017;8(25):41538–48. doi:10.18632/oncotarget.14582.
   PubMedGoogle Scholar
• Yang D-H, Kim M-H, Hong CY, Lee Y-K, Jin C-J, Pham TNN, Ahn J-S, Bae W-K, Kim Y-K, Chung I-J, et al. Alpha-type 1-polarized dendritic cells loaded with apoptotic allogeneic myeloma cell line induce strong CTL responses against autologous myeloma cells. Ann Hematol. 2010;89(8):795–801. doi:10.1007/s00277-010-0931-3.
   PubMed Web of Science ®Google Scholar
• Lee JJ, Choi B-H, Kang H-K, Park M-S, Park J-S, Kim S-K, Pham TNN, Cho D, Nam J-H, Kim Y-J, et al. Induction of multiple myeloma-specific cytotoxic T lymphocyte stimulation by dendritic cell pulsing with purified and optimized myeloma cell lysates. Leuk Lymphoma. 2007;48(10):2022–31. doi:10.1080/10428190701583975.
   PubMed Web of Science ®Google Scholar
• Ikuta Y, Katayama N, Wang L, Okugawa T, Takahashi Y, Schmitt M, Gu X, Watanabe M, Akiyoshi K, Nakamura H, et al. Presentation of a major histocompatibility complex class 1-binding peptide by monocyte-derived dendritic cells incorporating hydrophobized polysaccharide-truncated HER2 protein complex: implications for a polyvalent immuno-cell therapy. Blood. 2002;99(10):3717–24. doi:10.1182/blood.V99.10.3717.
   PubMed Web of Science ®Google Scholar
• Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 2002;359:1011–18.
   PubMed Web of Science ®Google Scholar
• Sanchez-Paulete AR, Teijeira A, Cueto FJ, Garasa S, Pérez-Gracia JL, Sánchez-Arráez A, Sancho D, Melero I. Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy. Ann Oncol. 2017;28(suppl_12):xii74. doi:10.1093/annonc/mdx727.
   PubMedGoogle Scholar
• Wu S, Chen X, Tang Y, Zhang Y, Li D, Chen J, Wang J, Tang Z, Zang G, Yu Y. Delivery of Tapasin-modified CTL epitope peptide via cytoplasmic transduction peptide induces CTLs by JAK/STAT signaling pathway in vivo. Acta Biochim Biophys Sin (Shanghai). 2018;50(2):181–90. doi:10.1093/abbs/gmx133.
   PubMed Web of Science ®Google Scholar
• Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H, Elisseeva OA, Oji Y, Kawakami M, Ikegame K, et al. Induction of WT1 (Wilms’ tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. The National Academy of Sciences of the USA; 2004; 101(38):13885–90. doi:10.1073/pnas.04058841010.
   Google Scholar
• Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, et al. The prioritization of cancer antigens: A national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009;15(17):5323–37. doi:10.1158/1078-0432.CCR-09-0737.
   PubMed Web of Science ®Google Scholar
• Garg H, Suri P, Gupta JC, Talwar GP, Dubey S. Survivin: a unique target for tumor therapy. Cancer Cell Int. 2016;16(1):49. doi:10.1186/s12935-016-0326-1.
   PubMedGoogle Scholar
• Fenstermaker RA, Ciesielski MJ, Qiu J, Yang N, Frank CL, Lee KP, Mechtler LR, Belal A, Ahluwalia MS, Hutson AD. Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma. Cancer Immunol Immunother. 2016;65(11):1339–52. doi:10.1007/s00262-016-1890-x.
   PubMed Web of Science ®Google Scholar
• Hamza T, Barnett JB, Li B. Interleukin 12 a key immunoregulatory cytokine in infection applications. Int J Mol Sci. 2010;11(3):789–806. doi:10.3390/ijms11030789.
   PubMed Web of Science ®Google Scholar
• Tuettenberg A, Fondel S, Steinbrink K, Enk AH, Jonuleit H. CD40 signalling induces IL-10-producing, tolerogenic dendritic cells. Exp Dermatol. 2010;19(1):44–53. doi:10.1111/j.1600-0625.2009.00975.x.
   PubMed Web of Science ®Google Scholar
• Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439(7077):682–87. doi:10.1038/nature04444.
   PubMed Web of Science ®Google Scholar
• Fife BT, Pauken KE. The role of the PD-1 pathway in autoimmunity and peripheral tolerance. Ann N Y Acad Sci. 2011;1217:45–59. doi:10.1111/j.1749-6632.2010.05919.x.
   PubMed Web of Science ®Google Scholar
• Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20(19):5064–74. doi:10.1158/1078-0432.CCR-13-3271.
   PubMed Web of Science ®Google Scholar
• Wang X, Guo G, Guan H, Yu Y, Lu J, Yu J. Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma. J Expe Clin Cancer Re. 2019;38(1):87. doi:10.1186/s13046-019-1085-3.
   PubMedGoogle Scholar
• Lou Y, Shi J, Guo D, Qureshi AK, Song L. Function of PD-L1 in antitumor immunity of glioma cells Saudi J Biol Sci. 201724(4):803–07. doi:10.1016/j.sjbs.2015.06.025.
   Google Scholar
• Wang CY, Thudium KB, Han M, Wang X-T, Huang H, Feingersh D, Garcia C, Wu Y, Kuhne M, Srinivasan M, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res. 2014;2(9):846–56. doi:10.1158/2326-6066.CIR-14-0040.
   PubMed Web of Science ®Google Scholar